Medical university of vienna, University in Vienna, Austria

London, April 6 Austrian scientists have developed a novel Covid-19 vaccine that has shown to be effective against all SARS-CoV-2 variants known to date, including Omicron.The preclinical data for the antigen-based vaccine developed by a team at Medical University of Vienna showed that it targets the receptor binding domains (RBD) of the SARS-CoV-2, the virus causing Covid, and induces a robust and uniform RBD-specific IgG antibody response in animal models and in human tests.This antibody response prevents the virus from docking onto and entering the body's cells, so that infection cannot occur.The findings, published in the leading journal Allergy, showed the vaccine to be effective even in those who have not yet built up any immunity as a result of vaccination."Our data give us grounds to hope that this readily producible protein-based vaccine antigen will be effective against all SARS-CoV-2 variants known to date, including Omicron," said study leader Rudolf Valenta, from the varsity's Centre for Pathophysiology, Infectiology and Immunology."The vaccine is designed to enable repeated injections to build up sustained sterilising immunity, is suitable for use in all age and risk groups and appears to be superior to currently available vaccines when it comes to inducing neutralising antibodies," he added.The SARS-CoV-2 subunit vaccine (PreS-RBD) is based on a structurally folded fusion protein consisting of two receptor binding domains (RBD) of the SARS-CoV-2 virus and the PreS antigen from hepatitis B, which serve as immunological carriers for each other, thereby strengthening the immune response.Currently available genetic Covid vaccines induce mainly transient IgG1 antibody responses, whereas the PreS-RBD vaccine can additionally induce long-lived RBD-specific IgG4 antibodies.PreS-RBD-specific IgG antibodies detected in blood and mucosal secretions reacted with SARS-CoV-2 variants, including the Omicron variant.Antibodies induced by vaccination with PreS-RBD more potently inhibited the binding of RBD with its human receptor ACE2, and their virus-neutralising titres were higher than those in a random sample of individuals fully immunised with two vaccinations of currently registered vaccines or than those of Covid-19 convalescents (that is, individuals who had previously had Covid)."The PreS-RBD vaccine has the potential to induce sterilising immunity to old and new SARS-CoV-2 variants by preventing infection by stopping viral replication and transmission through the inhibition of cellular virus entry," Valenta said.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Medical University Of ViennaFOLLOW

Medical university of vienna, Latest News

According to a new study from the Medical University of Vienna, viral infections during pregnancy have an impact on the mother's brain and postpartum behaviour. ...

Vienna, May 23 Austrian President Alexander Van der Bellen has announced that he is running for a second ... ...

Moscow, April 27 Austria has accepted the new ruble gas payment mechanism, introduced by Russia earlier this month, ... ...

The International Atomic Energy Agency (IAEA) said Friday its expert mission would travel to Ukraine's Chernobyl nuclear power plant on April 26 to help ensure the facility's safety. ...

Nagpur, Feb 28 As many as eight Indian girls have qualified for the main draw in MSLTA Women's $ ... ...

Los Angeles, April 18 Actress and comedienne Rebel Wilson has shared the secret behind her remarkable weight loss ... ...

A new study has suggested that people with cancer and non-O blood types, such as types A, B, and AB, face an increased risk of developing venous thromboembolism (VTE), or blood clots in the veins, three months after their initial diagnosis. ...

London, April 6 Austrian scientists have developed a novel Covid-19 vaccine that has shown to be effective against ... ...